The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden administration that would have allowed Medicare and Medicaid ...

The previous administration attempted to have Medicare Part D and Medicaid cover anti-obesity drugs under the Contract Year 2026 MA and Part D rule, which would have substantially increased access ...

Plan to cover anti-obesity drugs through Medicare ... Benefits consultant Mercer has said that 44% of U.S. companies with 500 or more employees covered obesity drugs last year. Medicare does ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded coverage of costly anti-obesity drugs to more than 7 million Americans on ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government’s Medicare program.

The state’s Medicaid program alone shoulders $868 million per year in obesity-related expenses. Anti-obesity medicines also save employers money, as a recent study has found .

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its ...

Obesity is linked to over 230 serious health conditions, causes more than 25,000 premature deaths a year in our state, and is responsible for $2 billion a year in annual ...

In November last year, the Biden administration proposed a new rule that would allow drugs like Wegovy and Zepbound to be covered by Medicare and Medicaid, expanding access for roughly 3.4 million ...